Showing 3541-3550 of 5693 results for "".
- Annexon Completes Enrollment in Phase 3 ARCHER II Trial of Vonaprument for GAhttps://modernod.com/news/annexon-completes-enrollment-in-phase-3-archer-ii-trial-of-vonaprument-for-ga/2482901/Annexon announced enrollment has been completed in the phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company remains on track to report topline data in the second half of 2026. Accordin
- EssilorLuxottica to Acquire Ophthalmic Lens Materials Division of PUcorehttps://modernod.com/news/essilorluxottica-to-acquire-ophthalmic-lens-materials-division-of-pucore/2482895/EssilorLuxottica has signed an agreement with the South Korean-based PUcore for the acquisition of all its assets and entities involved in the development, manufacturing and sale of monomers used in the production of high index ophthalmic lenses. The assets acquired by EssilorLuxottica inclu
- Topcon Partners with OKKO Health to Advance Home-Based Vision Monitoring and Patient Engagementhttps://modernod.com/news/topcon-partners-with-okko-health-to-advance-home-based-vision-monitoring-and-patient-engagement/2482894/Topcon Healthcare announced an investment in OKKO Health, a UK-based provider of vision testing software. While financial terms of the deal were not disclosed, the investment positions Topcon as the lead in OKKO Health’s seed funding round.
- Viatris Fails Phase 3 Study of MR-139 for Blepharitishttps://modernod.com/news/viatris-fails-phase-3-study-of-mr-139-for-blepharitis/2482893/Viatris announced that its phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. The MR-139 3001 phase 3 trial cons
- Harrow Enters into Commercialization Agreement with Samsung Bioepis for Biosimilars Portfolio in the UShttps://modernod.com/news/harrow-enters-into-commercialization-agreement-with-samsung-bioepis-for-ophthalmology-biosimilars-portfolio-in-the-us/2482890/Harrow announced that it has entered into a definitive agreement with Samsung Bioepis to secure the exclusive US commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis, which includes Byooviz (ranibizumab-nuna), an FDA-ap
- Nicox and Kowa Sign Agreement for Exclusive Rights to Glaucoma Treatment NCX 470 in US and Unlicensed Territorieshttps://modernod.com/news/nicox-and-kowa-sign-agreement-for-exclusive-rights-to-glaucoma-treatment-ncx-470-in-us-and-all-unlicensed-territories/2482889/Kowa has gained exclusive rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension in the US and all other territories of the world excludin
- EyeDura's Sustained-Release Eye Drop Technology Wins Industry Honorshttps://modernod.com/news/eyeduras-sustained-release-eye-drop-technology-wins-industry-honors/2482886/EyeDura Therapeutics, developer of preservative-free sustained release ophthalmic therapies, announced it received top recognition at two major industry forums among a field of ophthalmic startup companies. EyeDura won 'The Winning Pitch' challeng
- AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into Phase 1/2 Clinical Trialhttps://modernod.com/news/aavantgarde-receives-fda-clearance-to-progress-stargardt-disease-asset-aavb-039-into-phase-12-clinical-trial/2482885/AAVantgarde Bio announced that the FDA has cleared its investigational new drug (IND) application for AAVB-039, the company’s gene therapy program for Stargardt disease. AAVantgarde is now initiating CELESTE, a first-in-human phase 1/2 clinical trial in the United States to e
- Alcon Receives Health Canada Approval for Unity VCShttps://modernod.com/news/alcons-receives-health-canada-approval-for-unity-vcs/2482882/Alcon announced that Unity Vitreoretinal Cataract System (VCS) has received Health Canada approval. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon’s current leading systems, Constellation Vision System for vitreoretinal and combined proce
- The Vision Council Comments on Impact of Proposed Tariffs on Optical Industryhttps://modernod.com/news/the-vision-council-comments-on-impact-of-proposed-tariffs-on-optical-industry/2482880/The Vision Council has released a letter summarizing the recent tariffs proposed by the Trump administration and the impact it could have on the optical industry. The White House issued formal notice to several US trading partners outlining tariff